Edition:
United States

Biotest AG (BIOG_p.DE)

BIOG_p.DE on Xetra

27.25EUR
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
€27.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
39,358
52-wk High
€27.70
52-wk Low
€16.89

Chart for

About

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactur... (more)
No analyst recommendations are available for .

Overall

Beta: 0.63
Market Cap(Mil.): €1,159.44
Shares Outstanding(Mil.): 39.57
Dividend: 0.05
Yield (%): 0.16

Financials

  Industry Sector
P/E (TTM): -- 32.03 17.27
EPS (TTM): -- -- --
ROI: -- 14.00 35.43
ROE: -- 15.34 17.10

BRIEF-Biotest says Tiancheng to enter into domination agreement

* DGAP-ADHOC: BIOTEST AG: TIANCHENG INTENDS TO ENTER INTO A DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT WITH BIOTEST AG

Feb 08 2018

BRIEF-Biotest: Creat Takeover Of Biotest Closed

* MAJORITY SHAREHOLDING (APPROX. 90% OF BIOTEST'S ORDINARY SHARES AND VOTING SHARE CAPITAL) OF CREAT IN BIOTEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 31 2018

Biotest sheds U.S. business to allay U.S. concerns of Chinese takeover

FRANKFURT Biotest said on Friday that it has sold its U.S. operations, allaying national security concerns by U.S. authorities and paving the way for the German company's sale to a Chinese investor.

Jan 19 2018

BRIEF-Biotest: All Conditions Met For Creat Takeover Of Biotest

* DGAP-ADHOC: BIOTEST AG: ALL CONDITIONS MET FOR CREAT TAKEOVER OF BIOTEST

Jan 19 2018

BRIEF-Biotest: Trimodulin Concept For Phase III Study Coordinated With The Authorities

* DGAP-NEWS: BIOTEST AG: TRIMODULIN: CONCEPT FOR PHASE III STUDY SUCCESSFULLY COORDINATED WITH THE AUTHORITIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Dec 20 2017

BRIEF-Biotest 9-mth revenue at EUR 377.8 mln

* DGAP-NEWS: BIOTEST AG: BIOTEST GENERATES REVENUES OF EUR 377.8 MILLION IN THE FIRST NINE MONTHS 2017

Nov 14 2017

UPDATE 1-Takeover of plasma firm Biotest by China's Creat hits wall in U.S.

* Biotest shares drop 12 percent to 7-month low (Adds share price, background)

Nov 07 2017

China's Creat suffers setback in Biotest deal on U.S. scrutiny

FRANKFURT Chinese investor Creat Group Corp has withdrawn its application for U.S. approval of a planned 1.3-billion-euro ($1.51-billion) takeover of Biotest , the German blood plasma products maker said, sending its shares sharply lower.

Nov 07 2017

BRIEF-Biotest: Tiancheng withdrawal of application of transaction from CFIUS and refiling

* ‍TENDER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG​

Nov 07 2017

Earnings vs. Estimates